Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yosuke Kanno has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Osamu Matsuo

    Department of Physiology and Regenerative Medicine, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan

    12 shared publications
  • Hiroyuki Matsuno

    Department of Clinical Pathological Biochemistry, Faculty of Pharmaceutical Science, Doshisha Women's Collage of Liberal Arts, 97-1 Kodo Kyo-tanabe, Kyoto, 610-0395, Japan

    8 shared publications
  • Mariko Seishima

    Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan

    8 shared publications
  • Kiyotaka Okada

    Department of Physiology II. Kinki University School of Medicine, Osaka-sayama, Japan

    7 shared publications
  • Shigeru Ueshima

    1] Department of Physiology II. Kinki University School of Medicine, Osaka-sayama, Japan [2] Department of Food Science and Nutrition, Kinki University School of Agriculture, Nara, Japan

    7 shared publications
  • Eri Kawashita

    Department of Clinical Pathological Biochemistry, Faculty of Pharmaceutical Science, Doshisha Women's College of Liberal Arts, 97-1 Kodo Kyo-tanabe, Kyoto 610-0395, Japan

    6 shared publications

Latest Publications

  • Open Access

    Pathogenic and Regulatory Roles of Fibrinolytic Factors in Autoimmune Diseases

    by Yosuke Kanno

    Autoimmune diseases arise from complex interactions of genetic, environmental, and hormonal factors, yet their precise causes remain elusive. Beyond its canonical role in fibrin degradation, the fibrinolytic system is increasingly recognized as both a pathogenic driver and a regulatory modulator in autoimmunity. Key factors—plasminogen (Plg), plasmin, α2-antiplasmin (α2AP), tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), its receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1)—not only reflect secondary responses to vascular and immune dysregulation but also actively shape innate and adaptive immunity. They influence macrophage activation, dendritic cell maturation, T cell responses, and cytokine production, thereby bridging coagulation, inflammation, and tissue repair. This review integrates current evidence on the dual pathogenic and regulatory roles of fibrinolytic factors, organizing autoimmune diseases into systemic, organ-specific, and secondary syndromes. We further discuss how the imbalance of fibrinolysis can either promote inflammatory persistence or, conversely, facilitate resolution through fibrin clearance and immune homeostasis. By highlighting this bidirectional influence, the review aims to refine our understanding of fibrinolytic components as both contributors to and regulators of autoimmune disease pathogenesis.


  • Open Access

    The Roles of Fibrinolytic Factors in Bone Destruction Caused by Inflammation

    by Yosuke Kanno

    Chronic inflammatory diseases, such as rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, Crohn’s disease, periodontitis, and carcinoma metastasis frequently result in bone destruction. Pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6, and IL-17 are known to influence bone loss by promoting the differentiation and activation of osteoclasts. Fibrinolytic factors, such as plasminogen (Plg), plasmin, urokinase-type plasminogen activator (uPA), its receptor (uPAR), tissue-type plasminogen activator (tPA), α2-antiplasmin (α2AP), and plasminogen activator inhibitor-1 (PAI-1) are expressed in osteoclasts and osteoblasts and are considered essential in maintaining bone homeostasis by regulating the functions of both osteoclasts and osteoblasts. Additionally, fibrinolytic factors are associated with the regulation of inflammation and the immune system. This review explores the roles of fibrinolytic factors in bone destruction caused by inflammation.


  • α2-Antiplasmin is associated with macrophage activation and fibrin deposition in a macrophage activation syndrome mouse model

    by Yosuke Kanno, Kinomi Toyama, Haruna Shibata, Osamu Matsuo, Kei-Ichi Ozaki

    Macrophage activation syndrome (MAS) is a life-threatening condition, characterized by cytopenia, multi-organ dysfunction, and coagulopathy associated with excessive activation of macrophages. In this study, we investigated the roles of alpha2-antiplasmin (α2AP) in the progression of MAS using fulminant MAS mouse model induced by toll-like receptor-9 agonist (CpG) and D-(+)-galactosamine hydrochloride (DG). α2AP deficiency attenuated macrophage accumulation, liver injury, and fibrin deposition in the MAS model mice. Interferon-γ (IFN-γ) is associated with macrophage activation, including migration, and plays a pivotal role in MAS progression. α2AP enhanced the IFN-γ-induced migration, and tissue factor production. Additionally, we showed that fibrin-induced macrophage activation and tumor necrosis factor-α production. Moreover, the blockade of α2AP by neutralizing antibodies attenuated macrophage accumulation, liver injury, and fibrin deposition in the MAS model mice. These data suggest that α2AP may regulate IFN-γ-induced responses and be associated with macrophage activation and fibrin deposition in the MAS progression.


  • Open Access

    α2-antiplasmin is a key regulator of macrophage activation syndrome progression through modulation of IFN-γ-induced responses and fibrin deposition

    by Yosuke Kanno, Kinomi Toyama, Haruna Shibata, Osamu Matsuo, Kei-Ichi Ozaki

    Background: Macrophage activation syndrome (MAS) is a life-threatening condition, characterized by cytopenia, multi-organ dysfunction, and coagulopathy associated with excessive activation of macrophages. The aim of this study was to clarify the role of a2-antiplasmin (α2AP) in the pathogenesis of MAS. Methods: We investigated the role of α2AP in the progression of MAS using fulminant MAS mouse model induced by Toll-like receptor-9 (TLR-9) agonist (CpG) and d-galactosamine (DG). Results: α2AP deficiency attenuated macrophage accumulation, hypocellular bone marrow (BM), liver damage, and fibrin deposition in the MAS model mice. Interferon-g (IFN-γ) is associated with macrophage activation, including phagocytosis, invasion, and migration, and plays a pivotal role in MAS progression. α2AP enhanced the IFN-γ-induced phagocytosis, invasion, migration, and tissue factor (TF) production. Additionally, we showed that fibrin induced macrophage activation and tumor necrosis factor-a (TNF-α) production. Moreover, the blockade of α2AP by neutralizing antibodies attenuated macrophage accumulation, hypocellular BM, liver damage, and fibrin deposition in the MAS model mice. Conclusion: α2AP regulates macrophage activation through modulation of IFN-γ-induced responses and fibrin deposition and is associated with MAS progression.

  • Open Access

    The uPA/uPAR System Orchestrates the Inflammatory Response, Vascular Homeostasis, and Immune System in Fibrosis Progression

    by Yosuke Kanno

    Fibrotic diseases, such as systemic sclerosis (SSc), idiopathic pulmonary fibrosis, renal fibrosis and liver cirrhosis are characterized by tissue overgrowth due to excessive extracellular matrix (ECM) deposition. Fibrosis progression is caused by ECM overproduction and the inhibition of ECM degradation due to several events, including inflammation, vascular endothelial dysfunction, and immune abnormalities. Recently, it has been reported that urokinase plasminogen activator (uPA) and its receptor (uPAR), known to be fibrinolytic factors, orchestrate the inflammatory response, vascular homeostasis, and immune homeostasis system. The uPA/uPAR system may show promise as a potential therapeutic target for fibrotic diseases. This review considers the role of the uPA/uPAR system in the progression of fibrotic diseases.


  • Open Access

    α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis

    by Yosuke Kanno, En Shu

    Systemic sclerosis is a connective tissue disease of unknown origin that is characterized by immune system abnormalities, vascular damage, and extensive fibrosis of the skin and visceral organs. α2-antiplasmin is known to be the main plasmin inhibitor and has various functions such as cell differentiation and cytokine production, as well as the regulation of the maintenance of the immune system, endothelial homeostasis, and extracellular matrix metabolism. The expression of α2-antiplasmin is elevated in dermal fibroblasts from systemic sclerosis patients, and the blockade of α2-antiplasmin suppresses fibrosis progression and vascular dysfunction in systemic sclerosis model mice. α2-antiplasmin may have promise as a potential therapeutic target for systemic sclerosis. This review considers the role of α2-antiplasmin in the progression of systemic sclerosis.


  • α2-antiplasmin positively regulates endothelial-to-mesenchymal transition and fibrosis progression in diabetic nephropathy

    by Yosuke Kanno, Momoko Hirota, Osamu Matsuo, Kei-Ichi Ozaki

    Background Diabetic nephropathy (DN), is microvascular complication of diabetes causes to kidney dysfunction and renal fibrosis. It is known that hyperglycemia and advanced glycation end products (AGEs) produced by hyperglycemic condition induce myofibroblast differentiation and endothelial-to-mesenchymal transition (EndoMT), and exacerbate fibrosis in DN. Recently, we demonstrated that α2-antiplasmin (α2AP) is associated with inflammatory response and fibrosis progression. Methods We investigated the role of α2AP on fibrosis progression in DN using a streptozotocin-induced DN mouse model. Results α2AP deficiency attenuated EndoMT and fibrosis progression in DN model mice. We also showed that the high glucose condition/AGEs induced α2AP production in fibroblasts (FBs), and the reduction of receptor for AGEs (RAGE) by siRNA attenuated the AGEs-induced α2AP production in FBs. Furthermore, the bloackade of α2AP by the neutralizing antibody attenuated the high glucose condition-induced pro-fibrotic changes in FBs. On the other hand, the hyperglycemic condition/AGEs induced EndoMT in vascular endothelial cells (ECs), the FBs/ECs co-culture promoted the high glucose condition-induced EndoMT compared to ECs mono-culture. Furthermore, α2AP promoted the AGEs-induced EndoMT, and the blockade of α2AP attenuated the FBs/ECs co-culture-promoted EndoMT under the high glucose condition. Conclusions The high glucose conditions induced α2AP production, and α2AP is associated with EndoMT and fibrosis progression in DN. These findings provide a basis for clinical strategies to improve DN.


  • Alpha2-antiplasmin deficiency affects depression and anxiety-like behavior and apoptosis induced by stress in mice

    by Yosuke Kanno, Kaho Tsuchida, Chihiro Maruyama, Kyoko Hori, Hanako Teramura, Shiho Asahi, Osamu Matsuo, Kei-Ichi Ozaki

    Objectives: Depression is a psychiatric disorder that affects about 10% of the world’s population and is accompanied by anxiety. Depression and anxiety are often caused by various stresses. However, the etiology of depression and anxiety remains unknown. It has been reported that alpha2-antiplasmin ( α 2AP) not only inhibits plasmin but also has various functions such as cytokine production and cell growth. This study aimed to determine the roles of α 2AP on the stress-induced depression and anxiety. Methods: We investigated the mild repeated restraint stress-induced depressive and anxiety-like behavior in the α 2AP +/+ and α 2AP −/− mice using the social interaction test (SIT), sucrose preference test (SPT), and elevated plus maze (EPM). Results: The stresses such as the mild repeated restraint stress suppressed α 2AP expression in the hippocampus of mice, and the treatment of fluoxetine (selective serotonin reuptake inhibitor [SSRI]) recovered the stress-caused α 2AP suppression. We also showed that α 2AP deficiency promoted the mild restraint stress-stimulated depression-like behavior such as social withdrawal and apathy and apoptosis in mice. In contrast, α 2AP deficiency attenuated the mild restraint stress induced the anxiety-like behavior in mice. Conclusions: α 2AP affects the pathogenesis of depression and anxiety induced by stress.


  • MicroRNA-30c attenuates fibrosis progression and vascular dysfunction in systemic sclerosis model mice

    by Yosuke Kanno, En Shu, Hirofumi Niwa, Mariko Seishima, Kei-Ichi Ozaki

    Systemic sclerosis (SSc) is characterized by peripheral circulatory disturbance and fibrosis in skin and visceral organs. We recently demonstrated that α2-antiplasmin (α2AP) is elevated in SSc dermal fibroblasts and SSc model mice, and is associated with fibrosis progression and vascular dysfunction. In the present study, we predicted that α2AP could be a target of microRNA-30c (miR-30c) using TargetScan online database, and investigated the effect of miR-30c on the pathogenesis of SSc using a bleomycin-induced SSc model mice. miR-30c attenuated α2AP expression, and prevented the pro-fibrotic changes (increased dermal thickness, collagen deposition, myofibroblast accmulation) and the vascular dysfunction (the reduction of vascular endothelial cells (ECs) and blood flow) in the skin of SSc model mice. Furthermore, miR-30c suppressed pulmonary fibrosis progression in the SSc model mice. miR-30c exerts the anti-fibrotic and anti-angiopathy effects on SSc model mice, and might provide a basis for clinical strategies for SSc.


  • Open Access

    microRNA-30c attenuates fibrosis progression and vascular dysfunction in systemic sclerosis model mice

    by Yosuke Kanno, En Shu, Hirofumi Niwa, Mariko Seishima, Kei-Ichi Ozaki

    Systemic sclerosis (SSc) is characterized by the fibrosis of skin and visceral organs, and peripheral circulatory disturbance. We recently demonstrated that α2-antiplasmin (α2AP) is elevated in SSc dermal fibroblasts and SSc model mice, and is associated with fibrosis progression and vascular dysfunction. In the present study, we predicted that α2AP could be a target of microRNA-30c (miR-30c) using TargetScan online database, and investigated the effect of miR-30c on the pathogenesis of SSc using a bleomycin-induced SSc model mice. miR-30c attenuated α2AP expression, and prevented the pro-fibrotic changes (increased dermal thickness, collagen deposition, myofibroblast accmulation) and the vascular dysfunction (the reduction of vascular endothelial cells (ECs) and blood flow) in the skin of SSc model mice. Furthermore, miR-30c suppressed pulmonary fibrosis progression in the SSc model mice. These findings suggest that miR-30c exerts the anti-fibrotic and anti-angiopathy effects on SSc model mice, and might provide a basis for clinical strategies for SSc.